Home › Kanser sa Salivary Gland › New York
Pag-aaral pangklinika para sa Kanser sa Salivary Gland sa New York
5 pag-aaral para sa Kanser sa Salivary Gland ang naghahanap ng mga kalahok sa mga site sa New York.
Mga Lungsod sa New York
Opisyal na teksto ng pag-aaral (English)
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- Mount Sinai Hospital, New York
- at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05408845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Memorial Sloan Kettering Cancer Center, New York
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT06695845Integrated Cancer Repository for Cancer Research
- C.R. Wood Cancer Center, Glens Falls Hospital, Glens Falls
- Faxton St. Luke's Healthcare, Mohawk Valley, Utica
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT04620187VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Weill Cornell Medicine, Cornell University (site 126), New York
Nagre-recruitPhase 1/2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Dis 11, 2025 · NCT03556228Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.